<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;ff=20240413040800&amp;fc=20230708114047&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;ff=20240413040800&amp;fc=20230708114047&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Sat, 13 Apr 2024 08:08:02 +0000</lastbuilddate>
<pubDate>Fri, 12 Apr 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Peripheral artery disease and outcomes: how can we improve risk prediction?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38607986/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240413040800&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 12:ehae154. doi: 10.1093/eurheartj/ehae154. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38607986/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240413040800&v=2.18.0.post9+e462414">38607986</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae154>10.1093/eurheartj/ehae154</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38607986</guid>
<pubDate>Fri, 12 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Mounica Yanamandala</dc:creator>
<dc:creator>Guillaume Goudot</dc:creator>
<dc:creator>Marie Denise Gerhard-Herman</dc:creator>
<dc:date>2024-04-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Peripheral artery disease and outcomes: how can we improve risk prediction?</dc:title>
<dc:identifier>pmid:38607986</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae154</dc:identifier>
</item>
<item>
<title>Rescue of cardiac dysfunction during chemotherapy in acute myeloid leukaemia by blocking IL-1α</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38607560/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240413040800&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This study revealed that crosstalk between tumour cells and cardiomyocytes during chemotherapy could disturb cardiac energy metabolism and impair heart function. IL-1α neutralizing antibody treatment is a promising strategy for alleviating chemotherapy-induced cardiotoxicity in AML patients.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 12:ehae188. doi: 10.1093/eurheartj/ehae188. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Patients with acute myeloid leukaemia (AML) suffer from severe myocardial injury during daunorubicin (DNR)-based chemotherapy and are at high risk of cardiac mortality. The crosstalk between tumour cells and cardiomyocytes might play an important role in chemotherapy-related cardiotoxicity, but this has yet to be demonstrated. This study aimed to identify its underlying mechanism and explore potential therapeutic targets.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Cardiac tissues were harvested from an AML patient after DNR-based chemotherapy and were subjected to single-nucleus RNA sequencing. Cardiac metabolism and function were evaluated in AML mice after DNR treatment by using positron emission tomography, magnetic resonance imaging, and stable-isotope tracing metabolomics. Plasma cytokines were screened in AML mice after DNR treatment. Genetically modified mice and cell lines were used to validate the central role of the identified cytokine and explore its downstream effectors.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In the AML patient, disruption of cardiac metabolic homeostasis was associated with heart dysfunction after DNR-based chemotherapy. In AML mice, cardiac fatty acid utilization was attenuated, resulting in cardiac dysfunction after DNR treatment, but these phenotypes were not observed in similarly treated tumour-free mice. Furthermore, tumour cell-derived interleukin (IL)-1α was identified as a primary factor leading to DNR-induced cardiac dysfunction and administration of an anti-IL-1α neutralizing antibody could improve cardiac functions in AML mice after DNR treatment.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study revealed that crosstalk between tumour cells and cardiomyocytes during chemotherapy could disturb cardiac energy metabolism and impair heart function. IL-1α neutralizing antibody treatment is a promising strategy for alleviating chemotherapy-induced cardiotoxicity in AML patients.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38607560/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240413040800&v=2.18.0.post9+e462414">38607560</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae188>10.1093/eurheartj/ehae188</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38607560</guid>
<pubDate>Fri, 12 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Xingliang Zhou</dc:creator>
<dc:creator>Yiwei Liu</dc:creator>
<dc:creator>Yi Shen</dc:creator>
<dc:creator>Lijun Chen</dc:creator>
<dc:creator>Wenting Hu</dc:creator>
<dc:creator>Yi Yan</dc:creator>
<dc:creator>Bei Feng</dc:creator>
<dc:creator>Li Xiang</dc:creator>
<dc:creator>Yifan Zhu</dc:creator>
<dc:creator>Chenyu Jiang</dc:creator>
<dc:creator>Zihao Dai</dc:creator>
<dc:creator>Xu Huang</dc:creator>
<dc:creator>Liwei Wu</dc:creator>
<dc:creator>Tianyu Liu</dc:creator>
<dc:creator>Lijun Fu</dc:creator>
<dc:creator>Caiwen Duan</dc:creator>
<dc:creator>Shuhong Shen</dc:creator>
<dc:creator>Jun Li</dc:creator>
<dc:creator>Hao Zhang</dc:creator>
<dc:date>2024-04-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Rescue of cardiac dysfunction during chemotherapy in acute myeloid leukaemia by blocking IL-1α</dc:title>
<dc:identifier>pmid:38607560</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae188</dc:identifier>
</item>
<item>
<title>Prague ICU: free educational platform in the field of acute cardiovascular care</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38607441/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240413040800&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 12:ehae200. doi: 10.1093/eurheartj/ehae200. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38607441/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240413040800&v=2.18.0.post9+e462414">38607441</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae200>10.1093/eurheartj/ehae200</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38607441</guid>
<pubDate>Fri, 12 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Michal Pazdernik</dc:creator>
<dc:date>2024-04-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Prague ICU: free educational platform in the field of acute cardiovascular care</dc:title>
<dc:identifier>pmid:38607441</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae200</dc:identifier>
</item>
<item>
<title>The Nordic Cardio-Oncology Society: mission and future goals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38607440/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240413040800&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 12:ehae014. doi: 10.1093/eurheartj/ehae014. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38607440/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240413040800&v=2.18.0.post9+e462414">38607440</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae014>10.1093/eurheartj/ehae014</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38607440</guid>
<pubDate>Fri, 12 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Geeta Gulati</dc:creator>
<dc:creator>Agneta Månsson Broberg</dc:creator>
<dc:creator>Birgitte Vrou Offersen</dc:creator>
<dc:date>2024-04-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The Nordic Cardio-Oncology Society: mission and future goals</dc:title>
<dc:identifier>pmid:38607440</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae014</dc:identifier>
</item>
<item>
<title>New devices of transcatheter interventions for structural heart disease in China</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38607335/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240413040800&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 12:ehae172. doi: 10.1093/eurheartj/ehae172. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38607335/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240413040800&v=2.18.0.post9+e462414">38607335</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae172>10.1093/eurheartj/ehae172</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38607335</guid>
<pubDate>Fri, 12 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Yaling Han</dc:creator>
<dc:date>2024-04-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>New devices of transcatheter interventions for structural heart disease in China</dc:title>
<dc:identifier>pmid:38607335</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae172</dc:identifier>
</item>
<item>
<title>Sing for a long and healthy life?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38607286/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240413040800&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 12:ehad819. doi: 10.1093/eurheartj/ehad819. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38607286/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240413040800&v=2.18.0.post9+e462414">38607286</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad819>10.1093/eurheartj/ehad819</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38607286</guid>
<pubDate>Fri, 12 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Ragavendra R Baliga</dc:creator>
<dc:date>2024-04-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Sing for a long and healthy life?</dc:title>
<dc:identifier>pmid:38607286</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad819</dc:identifier>
</item>
<item>
<title>Atherosclerosis evaluation and cardiovascular risk estimation using coronary computed tomography angiography</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38606889/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240413040800&amp;v=2.18.0.post9+e462414
      <description>Clinical risk scores based on traditional risk factors of atherosclerosis correlate imprecisely to an individual's complex pathophysiological predisposition to atherosclerosis and provide limited accuracy for predicting major adverse cardiovascular events (MACE). Over the past two decades, computed tomography scanners and techniques for coronary computed tomography angiography (CCTA) analysis have substantially improved, enabling more precise atherosclerotic plaque quantification and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 12:ehae190. doi: 10.1093/eurheartj/ehae190. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Clinical risk scores based on traditional risk factors of atherosclerosis correlate imprecisely to an individual's complex pathophysiological predisposition to atherosclerosis and provide limited accuracy for predicting major adverse cardiovascular events (MACE). Over the past two decades, computed tomography scanners and techniques for coronary computed tomography angiography (CCTA) analysis have substantially improved, enabling more precise atherosclerotic plaque quantification and characterization. The accuracy of CCTA for quantifying stenosis and atherosclerosis has been validated in numerous multicentre studies and has shown consistent incremental prognostic value for MACE over the clinical risk spectrum in different populations. Serial CCTA studies have advanced our understanding of vascular biology and atherosclerotic disease progression. The direct disease visualization of CCTA has the potential to be used synergistically with indirect markers of risk to significantly improve prevention of MACE, pending large-scale randomized evaluation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38606889/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240413040800&v=2.18.0.post9+e462414">38606889</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae190>10.1093/eurheartj/ehae190</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38606889</guid>
<pubDate>Fri, 12 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Nick S Nurmohamed</dc:creator>
<dc:creator>Alexander R van Rosendael</dc:creator>
<dc:creator>Ibrahim Danad</dc:creator>
<dc:creator>Quyen Ngo-Metzger</dc:creator>
<dc:creator>Pam R Taub</dc:creator>
<dc:creator>Kausik K Ray</dc:creator>
<dc:creator>Gemma Figtree</dc:creator>
<dc:creator>Marc P Bonaca</dc:creator>
<dc:creator>Judith Hsia</dc:creator>
<dc:creator>Fatima Rodriguez</dc:creator>
<dc:creator>Alexander T Sandhu</dc:creator>
<dc:creator>Koen Nieman</dc:creator>
<dc:creator>James P Earls</dc:creator>
<dc:creator>Udo Hoffmann</dc:creator>
<dc:creator>Jeroen J Bax</dc:creator>
<dc:creator>James K Min</dc:creator>
<dc:creator>David J Maron</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:date>2024-04-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Atherosclerosis evaluation and cardiovascular risk estimation using coronary computed tomography angiography</dc:title>
<dc:identifier>pmid:38606889</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae190</dc:identifier>
</item>
<item>
<title>Rising stars in cardiology: George Abraham</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38606883/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240413040800&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 12:ehae192. doi: 10.1093/eurheartj/ehae192. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38606883/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240413040800&v=2.18.0.post9+e462414">38606883</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae192>10.1093/eurheartj/ehae192</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38606883</guid>
<pubDate>Fri, 12 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Judith Ozkan</dc:creator>
<dc:date>2024-04-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Rising stars in cardiology: George Abraham</dc:title>
<dc:identifier>pmid:38606883</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae192</dc:identifier>
</item>
<item>
<title>Rising stars in cardiology: Florian A. Wenzl</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38606876/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240413040800&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 12:ehae186. doi: 10.1093/eurheartj/ehae186. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38606876/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240413040800&v=2.18.0.post9+e462414">38606876</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae186>10.1093/eurheartj/ehae186</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38606876</guid>
<pubDate>Fri, 12 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Judith Ozkan</dc:creator>
<dc:date>2024-04-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Rising stars in cardiology: Florian A. Wenzl</dc:title>
<dc:identifier>pmid:38606876</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae186</dc:identifier>
</item>
<item>
<title>Leaders in cardiology: Renate Schnabel</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38606872/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240413040800&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 12:ehae182. doi: 10.1093/eurheartj/ehae182. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38606872/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240413040800&v=2.18.0.post9+e462414">38606872</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae182>10.1093/eurheartj/ehae182</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38606872</guid>
<pubDate>Fri, 12 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Judith Ozkan</dc:creator>
<dc:date>2024-04-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Leaders in cardiology: Renate Schnabel</dc:title>
<dc:identifier>pmid:38606872</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae182</dc:identifier>
</item>
<item>
<title>From chronic disease to chronic health: the evolving role of doctors in the 21st century</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38606857/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240413040800&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 12:ehae173. doi: 10.1093/eurheartj/ehae173. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38606857/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240413040800&v=2.18.0.post9+e462414">38606857</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae173>10.1093/eurheartj/ehae173</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38606857</guid>
<pubDate>Fri, 12 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Luigi Fontana</dc:creator>
<dc:date>2024-04-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>From chronic disease to chronic health: the evolving role of doctors in the 21st century</dc:title>
<dc:identifier>pmid:38606857</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae173</dc:identifier>
</item>
<item>
<title>Rising stars in cardiology: Tobias Harm</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38606853/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240413040800&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 12:ehae122. doi: 10.1093/eurheartj/ehae122. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38606853/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240413040800&v=2.18.0.post9+e462414">38606853</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae122>10.1093/eurheartj/ehae122</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38606853</guid>
<pubDate>Fri, 12 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Judith Ozkan</dc:creator>
<dc:date>2024-04-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Rising stars in cardiology: Tobias Harm</dc:title>
<dc:identifier>pmid:38606853</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae122</dc:identifier>
</item>
<item>
<title>Polygenic risk scores for cardiovascular risk prediction: moving towards implementation into clinical practice?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38606847/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240413040800&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 12:ehae125. doi: 10.1093/eurheartj/ehae125. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38606847/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240413040800&v=2.18.0.post9+e462414">38606847</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae125>10.1093/eurheartj/ehae125</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38606847</guid>
<pubDate>Fri, 12 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Mette Christoffersen</dc:creator>
<dc:creator>Stefan Stender</dc:creator>
<dc:creator>Anne Tybjærg-Hansen</dc:creator>
<dc:date>2024-04-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Polygenic risk scores for cardiovascular risk prediction: moving towards implementation into clinical practice?</dc:title>
<dc:identifier>pmid:38606847</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae125</dc:identifier>
</item>
<item>
<title>Rising standards and applying guidelines in sub-Saharan cardiology: CardioTan 2024 Heart Team Africa</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38606844/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240413040800&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 12:ehae181. doi: 10.1093/eurheartj/ehae181. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38606844/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240413040800&v=2.18.0.post9+e462414">38606844</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae181>10.1093/eurheartj/ehae181</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38606844</guid>
<pubDate>Fri, 12 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Delila Kimambo</dc:creator>
<dc:creator>Bartłomiej Guzik</dc:creator>
<dc:creator>Peter Kisenge</dc:creator>
<dc:date>2024-04-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Rising standards and applying guidelines in sub-Saharan cardiology: CardioTan 2024 Heart Team Africa</dc:title>
<dc:identifier>pmid:38606844</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae181</dc:identifier>
</item>
<item>
<title>Ischaemic stroke in women with atrial fibrillation: temporal trends and clinical implications</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38606837/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240413040800&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The association between female sex and IS rate has decreased and become non-significant over the course of the study period from 2007 to 2018, suggesting that female sex could be omitted as a factor when estimating expected IS rates and the need for OAC therapy in patients with AF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 12:ehae198. doi: 10.1093/eurheartj/ehae198. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Female sex has been linked with higher risk of ischaemic stroke (IS) in atrial fibrillation (AF), but no prior study has examined temporal trends in the IS risk associated with female sex.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The registry-linkage Finnish AntiCoagulation in Atrial Fibrillation (FinACAF) study included all patients with AF in Finland from 2007 to 2018. Ischaemic stroke rates and rate ratios were computed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Overall, 229 565 patients with new-onset AF were identified (50.0% women; mean age 72.7 years). The crude IS incidence was higher in women than in men across the entire study period (21.1 vs. 14.9 events per 1000 patient-years, P &lt; .001), and the incidence decreased both in men and women. In 2007-08, female sex was independently associated with a 20%-30% higher IS rate in the adjusted analyses, but this association attenuated and became statistically non-significant by the end of the observation period. Similar trends were observed when time with and without oral anticoagulant (OAC) treatment was analysed, as well as when only time without OAC use was considered. The decrease in IS rate was driven by patients with high IS risk, whereas in patients with low or moderate IS risk, female sex was not associated with a higher IS rate.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The association between female sex and IS rate has decreased and become non-significant over the course of the study period from 2007 to 2018, suggesting that female sex could be omitted as a factor when estimating expected IS rates and the need for OAC therapy in patients with AF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38606837/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240413040800&v=2.18.0.post9+e462414">38606837</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae198>10.1093/eurheartj/ehae198</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38606837</guid>
<pubDate>Fri, 12 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Konsta Teppo</dc:creator>
<dc:creator>K E Juhani Airaksinen</dc:creator>
<dc:creator>Jussi Jaakkola</dc:creator>
<dc:creator>Olli Halminen</dc:creator>
<dc:creator>Birgitta Salmela</dc:creator>
<dc:creator>Elis Kouki</dc:creator>
<dc:creator>Jari Haukka</dc:creator>
<dc:creator>Jukka Putaala</dc:creator>
<dc:creator>Miika Linna</dc:creator>
<dc:creator>Aapo L Aro</dc:creator>
<dc:creator>Pirjo Mustonen</dc:creator>
<dc:creator>Juha Hartikainen</dc:creator>
<dc:creator>Gregory Y H Lip</dc:creator>
<dc:creator>Mika Lehto</dc:creator>
<dc:date>2024-04-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Ischaemic stroke in women with atrial fibrillation: temporal trends and clinical implications</dc:title>
<dc:identifier>pmid:38606837</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae198</dc:identifier>
</item>
<item>
<title>Ten years of direct oral anticoagulants: lessons learned and challenges ahead</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38606835/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240413040800&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 12:ehae061. doi: 10.1093/eurheartj/ehae061. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38606835/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240413040800&v=2.18.0.post9+e462414">38606835</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae061>10.1093/eurheartj/ehae061</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38606835</guid>
<pubDate>Fri, 12 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>K E Juhani Airaksinen</dc:creator>
<dc:creator>Francesco De Sensi</dc:creator>
<dc:date>2024-04-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Ten years of direct oral anticoagulants: lessons learned and challenges ahead</dc:title>
<dc:identifier>pmid:38606835</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae061</dc:identifier>
</item>
<item>
<title>Positive Vasoreactivity Testing in Pulmonary Arterial Hypertension: Therapeutic Consequences, Treatment Patterns, and Outcomes in the Modern Management Era</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38606558/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240413040800&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our data display heterogeneity within the group of vasoresponders, with a large subset failing to show a sustained satisfactory clinical response to CCBs. This highlights the necessity for comprehensive reassessment during early follow-up. The use of pulmonary artery compliance in addition to current measures may better identify those likely to have a good long-term response.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 12. doi: 10.1161/CIRCULATIONAHA.122.063821. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Among patients with pulmonary arterial hypertension (PAH), acute vasoreactivity testing during right heart catheterization may identify acute vasoresponders, for whom treatment with high-dose calcium channel blockers (CCBs) is recommended. However, long-term outcomes in the current era remain largely unknown. We sought to evaluate the implications of acute vasoreactivity response for long-term response to CCBs and other outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients diagnosed with PAH between January 1999 and December 2018 at 15 pulmonary hypertension centers were included and analyzed retrospectively. In accordance with current guidelines, acute vasoreactivity response was defined by a decrease of mean pulmonary artery pressure by ≥10 mm Hg to reach &lt;40 mm Hg, without a decrease in cardiac output. Long-term response to CCBs was defined as alive with unchanged initial CCB therapy with or without other initial PAH therapy and World Health Organization functional classification I/II or low European Society of Cardiology/European Respiratory Society risk status at 12 months after initiation of CCBs. Patients were followed for up to 5 years; clinical measures, outcome, and subsequent treatment patterns were captured.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 3702 patients undergoing right heart catheterization for PAH diagnosis, 2051 had idiopathic, hereditary, or drug-induced PAH, of whom 1904 (92.8%) underwent acute vasoreactivity testing. A total of 162 patients fulfilled acute vasoreactivity response criteria and received an initial CCB alone (n=123) or in combination with another PAH therapy (n=39). The median follow-up time was 60.0 months (interquartile range, 30.8-60.0), during which overall survival was 86.7%. At 12 months, 53.2% remained on CCB monotherapy, 14.7% on initial CCB plus another initial PAH therapy, and the remaining patients had the CCB withdrawn or PAH therapy added. CCB long-term response was found in 54.3% of patients. Five-year survival was 98.5% in long-term responders versus 73.0% in nonresponders. In addition to established vasodilator responder criteria, pulmonary artery compliance at acute vasoreactivity testing, low risk status and NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels at early follow-up correlated with long-term response and predicted survival.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our data display heterogeneity within the group of vasoresponders, with a large subset failing to show a sustained satisfactory clinical response to CCBs. This highlights the necessity for comprehensive reassessment during early follow-up. The use of pulmonary artery compliance in addition to current measures may better identify those likely to have a good long-term response.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38606558/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240413040800&v=2.18.0.post9+e462414">38606558</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.122.063821>10.1161/CIRCULATIONAHA.122.063821</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38606558</guid>
<pubDate>Fri, 12 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Felix Gerhardt</dc:creator>
<dc:creator>Eva Fiessler</dc:creator>
<dc:creator>Karen M Olsson</dc:creator>
<dc:creator>Moritz Z Kayser</dc:creator>
<dc:creator>Gabor Kovacs</dc:creator>
<dc:creator>Henning Gall</dc:creator>
<dc:creator>H Ardeschir Ghofrani</dc:creator>
<dc:creator>Roza Badr Eslam</dc:creator>
<dc:creator>Irene M Lang</dc:creator>
<dc:creator>Nicola Benjamin</dc:creator>
<dc:creator>Ekkehard Grünig</dc:creator>
<dc:creator>Michael Halank</dc:creator>
<dc:creator>Tobias J Lange</dc:creator>
<dc:creator>Silvia Ulrich</dc:creator>
<dc:creator>Hanno Leuchte</dc:creator>
<dc:creator>Matthias Held</dc:creator>
<dc:creator>Hans Klose</dc:creator>
<dc:creator>Ralf Ewert</dc:creator>
<dc:creator>Heinrike Wilkens</dc:creator>
<dc:creator>Carmen Pizarro</dc:creator>
<dc:creator>Dirk Skowasch</dc:creator>
<dc:creator>Max Wissmüller</dc:creator>
<dc:creator>Martin Hellmich</dc:creator>
<dc:creator>Horst Olschewski</dc:creator>
<dc:creator>Marius M Hoeper</dc:creator>
<dc:creator>Stephan Rosenkranz</dc:creator>
<dc:date>2024-04-12</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Positive Vasoreactivity Testing in Pulmonary Arterial Hypertension: Therapeutic Consequences, Treatment Patterns, and Outcomes in the Modern Management Era</dc:title>
<dc:identifier>pmid:38606558</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.122.063821</dc:identifier>
</item>
<item>
<title>Time-series reconstruction of the molecular architecture of human centriole assembly</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38604175/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240413040800&amp;v=2.18.0.post9+e462414
      <description>Centriole biogenesis, as in most organelle assemblies, involves the sequential recruitment of sub-structural elements that will support its function. To uncover this process, we correlated the spatial location of 24 centriolar proteins with structural features using expansion microscopy. A time-series reconstruction of protein distributions throughout human procentriole assembly unveiled the molecular architecture of the centriole biogenesis steps. We found that the process initiates with the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Apr 5:S0092-8674(24)00316-7. doi: 10.1016/j.cell.2024.03.025. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Centriole biogenesis, as in most organelle assemblies, involves the sequential recruitment of sub-structural elements that will support its function. To uncover this process, we correlated the spatial location of 24 centriolar proteins with structural features using expansion microscopy. A time-series reconstruction of protein distributions throughout human procentriole assembly unveiled the molecular architecture of the centriole biogenesis steps. We found that the process initiates with the formation of a naked cartwheel devoid of microtubules. Next, the bloom phase progresses with microtubule blade assembly, concomitantly with radial separation and rapid cartwheel growth. In the subsequent elongation phase, the tubulin backbone grows linearly with the recruitment of the A-C linker, followed by proteins of the inner scaffold (IS). By following six structural modules, we modeled 4D assembly of the human centriole. Collectively, this work provides a framework to investigate the spatial and temporal assembly of large macromolecules.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38604175/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240413040800&v=2.18.0.post9+e462414">38604175</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.03.025>10.1016/j.cell.2024.03.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38604175</guid>
<pubDate>Thu, 11 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Marine H Laporte</dc:creator>
<dc:creator>Davide Gambarotto</dc:creator>
<dc:creator>Éloïse Bertiaux</dc:creator>
<dc:creator>Lorène Bournonville</dc:creator>
<dc:creator>Vincent Louvel</dc:creator>
<dc:creator>José M Nunes</dc:creator>
<dc:creator>Susanne Borgers</dc:creator>
<dc:creator>Virginie Hamel</dc:creator>
<dc:creator>Paul Guichard</dc:creator>
<dc:date>2024-04-11</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Time-series reconstruction of the molecular architecture of human centriole assembly</dc:title>
<dc:identifier>pmid:38604175</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.03.025</dc:identifier>
</item>
<item>
<title>Unveiling Platelets as Immune Regulatory Cells</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38603477/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240413040800&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Apr 12;134(8):987-989. doi: 10.1161/CIRCRESAHA.124.324167. Epub 2024 Apr 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38603477/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240413040800&v=2.18.0.post9+e462414">38603477</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324167>10.1161/CIRCRESAHA.124.324167</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38603477</guid>
<pubDate>Thu, 11 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Danielle Karakas</dc:creator>
<dc:creator>Heyu Ni</dc:creator>
<dc:date>2024-04-11</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Unveiling Platelets as Immune Regulatory Cells</dc:title>
<dc:identifier>pmid:38603477</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324167</dc:identifier>
</item>
<item>
<title>AKAP12 Overexpression Affects Cardiac Function via PDE8</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38603476/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240413040800&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Apr 12;134(8):1023-1025. doi: 10.1161/CIRCRESAHA.124.324475. Epub 2024 Apr 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38603476/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240413040800&v=2.18.0.post9+e462414">38603476</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324475>10.1161/CIRCRESAHA.124.324475</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38603476</guid>
<pubDate>Thu, 11 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Hariharan Subramanian</dc:creator>
<dc:creator>Viacheslav O Nikolaev</dc:creator>
<dc:date>2024-04-11</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>AKAP12 Overexpression Affects Cardiac Function via PDE8</dc:title>
<dc:identifier>pmid:38603476</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324475</dc:identifier>
</item>
<item>
<title>Correction to: Circadian Rhythms of the Blood-Brain Barrier and Drug Delivery</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38603475/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240413040800&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Apr 12;134(8):e92. doi: 10.1161/RES.0000000000000668. Epub 2024 Apr 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38603475/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240413040800&v=2.18.0.post9+e462414">38603475</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000668>10.1161/RES.0000000000000668</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38603475</guid>
<pubDate>Thu, 11 Apr 2024 06:00:00 -0400</pubDate>
<dc:date>2024-04-11</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Correction to: Circadian Rhythms of the Blood-Brain Barrier and Drug Delivery</dc:title>
<dc:identifier>pmid:38603475</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000668</dc:identifier>
</item>





























</channel>
</rss>